lutetium has been researched along with Lymphoma, Mantle-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahmad, HF; Burton, LP; Chaaya, G; Elajami, MK; Schwartz, M | 1 |
| Arndt, MA; Bötticher, B; Brem, G; Exner, E; Gröne, HJ; Grosse-Hovest, L; Haberkorn, U; Jäger, D; Keller, A; Krämer, S; Krauss, J; Leotta, K; Mier, W; Sauter, M; Strumberg, D; Weber, T; Wischnjow, A | 1 |
2 other study(ies) available for lutetium and Lymphoma, Mantle-Cell
| Article | Year |
|---|---|
Repurposed Effect of
Topics: Adult; Aged, 80 and over; Carcinoid Tumor; Humans; Lutetium; Lymphoma, Mantle-Cell; Male; Radiopharmaceuticals; Somatostatin | 2022 |
Preclinical evaluation of a diabody-based (177)Lu-radioimmunoconjugate for CD22-directed radioimmunotherapy in a non-Hodgkin lymphoma mouse model.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Burkitt Lymphoma; Cell Line, Tumor; Female; Forkhead Transcription Factors; Homeodomain Proteins; Humans; Immunoconjugates; Immunoglobulins, Intravenous; Interleukin Receptor Common gamma Subunit; Lutetium; Lymphoma, Mantle-Cell; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Radioimmunotherapy; Radioisotopes; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |